Peter Pisters is one of the top 10 CEOs, according to Glassdoor. Photo courtesy of MD Anderson

Three Houston-area CEOs are doing a exemplary job of leading, says a new report.

Dr. Peter Pisters (MD Anderson Cancer Center), Dr. Marc Boom (Houston Methodist), and Worthing Jackman (Waste Connections) appear on Glassdoor's new list of the top 100 CEOs for 2021.

Pisters scored particularly well; he ranked third overall on the prestigious list and earned a 99-percent approval rating from MD Anderson employees who shared anonymous feedback on the Glassdoor platform, which publishes reviews and salary information for employers.

Meanwhile, Boom ranked 60 overall with a 93 percent approval, while Jackman came in at 76 overall with a 92 percent approval.

Other Texas executives appearing on the new Glassdoor list are:

  • Seventh-ranked Charles Butt, CEO of San Antonio-based H-E-B (96 percent).
  • Fourth-ranked Gary Kelly, who just announced he's stepping down as CEO of Dallas-based Southwest Airlines (98 percent approval).
  • 55th-ranked Sean Yalamanchi, chairman and president of Richardson-based Infovision (93 percent approval).

"Over the past year, company leaders around the world faced unprecedented challenges to support employees during the COVID-19 crisis. Now, the employees have spoken and it's clear that these CEOs excelled and found new ways to support their people when the world of work flipped upside down," Christian Sutherland-Wong, Glassdoor's CEO, says in a news release.

------

This article originally ran on CultureMap.

Dr. Peter Pisters, president of MD Anderson, ranks high on the list of top CEOs. Photo courtesy of MD Anderson

Leading Houston healthcare executive named one of America's top CEOs

Best boss

Houston-based MD Anderson regularly garners praise for its breakthrough cancer treatments. Now, its leader is garnering attention as one of the country's top CEOs.

Dr. Peter Pisters, who's been president of MD Anderson Cancer Center in Houston since 2017, is among the honorees in Glassdoor's annual Employees' Choice Awards, recognizing the top 100 CEOs of 2019. Pisters ranks 47th on the list, with an impressive 94 percent approval rating from his employees. He appears in the category for large employers.

In a letter sent to faculty and staff after he was named to the position, Pisters wrote that he looked forward to collaborating with his new MD Anderson colleagues on the hospital's "profound purpose" of wiping out cancer.

"My promise to you is we will do so with a strong moral compass and principles of values-based servant leadership," Pisters wrote. "The honor of serving as your president is one that I both respect and am humbled by, and I will spare no effort in working with you to build upon and extend MD Anderson's unparalleled history of success."

Sitting atop the Glassdoor list of CEOs at large employers is Pat Gelsinger, CEO of VMWare. Charles Butt, chairman and CEO of San Antonio-based H-E-B, is in second place, followed by In-N-Out Burger's Lynsi Snyder, T-Mobile's John Legere, and Adobe's Shantanu Narayen.

"Under [Butt's] leadership, the desire to constantly innovate has led to new store concepts, the creation of one of the most successful private label programs in the country, and the commitment to build out state-of-the-art digital products and services to complement H-E-B's world-class stores," the company says in a release about the Glassdoor recognition.

The remaining Texans on the Glassdoor list are all from the Dallas area: Gary Kelly, chairman and CEO of Dallas-based Southwest Airlines; Peter Strebel, president of Dallas-based Omni Hotels & Resorts; and Steve Barick, chief operating officer of Irving-based Highgate Hotels, all in the category for large employers.

Kelly, who has worked at Southwest for more than 30 years, is the highest ranked CEO in Dallas, landing at No. 35 with an approval rating of 95 percent.

At No. 58 is Strebel, who garnered an approval rating of 94 percent. He's a longtime employee of Omni; in 2018, he was promoted to president.

Barick, the longtime chief operating officer of Irving-based Highgate Hotels, claims the 97th spot with an approval rating of 90 percent.

------

This article originally appeared on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston geothermal unicorn Fervo officially files for IPO

going public

Fervo Energy has officially filed for IPO.

The Houston-based geothermal unicorn filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission on April 17 to list its Class A common stock on the Nasdaq exchange. Fervo intends to be listed under the ticker symbol "FRVO."

The number and price of the shares have not yet been determined, according to a news release from Fervo. J.P. Morgan, BofA Securities, RBC Capital Markets and Barclays are leading the offering.

The highly anticipated filing comes as Fervo readies its flagship Cape Station geothermal project to deliver its first power later this year

"Today, miles-long lines for gasoline have been replaced by lines for electricity. Tech companies compete for megawatts to claim AI market share. Manufacturers jockey for power to strengthen American industry. Utilities demand clean, firm electricity to stabilize the grid," Fervo CEO Tim Latimer shared in the filing. "Fervo is prepared to serve all of these customers. Not with complex, idiosyncratic projects but with a simplified, standardized product capable of delivering around-the-clock, carbon-free power using proven oil and gas technology."

Fervo has been preparing to file for IPO for months. Axios Pro first reported that the company "quietly" filed for an IPO in January and estimated it would be valued between $2 billion and $3 billion.

Fervo also closed $421 million in non-recourse debt financing for the first phase of Cape Station last month and raised a $462 million Series E in December. The company also announced the addition of four heavyweights to its board of directors last week, including Meg Whitman, former CEO of eBay, Hewlett-Packard, and Spring-based HPE.

Fervo reported a net loss of $70.5 million for the 2025 fiscal year in the S-1 filing and a loss of $41.1 million in 2024.

Tracxn.com estimates that Fervo has raised $1.12 billion over 12 funding rounds. The company was founded in 2017 by Latimer and CTO Jack Norbeck.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

New UT Austin med center, anchored by MD Anderson, gets $1 billion gift

Future of Health

A donation announced Tuesday, April 21, breaks a major record at the University of Texas at Austin. Michael and Susan Dell are now UT Austin's first supporters to give $1 billion. In response, the university will create the UT Dell Campus for Advanced Research and the UT Dell Medical Center to "advance human health," per a press release.

The release also records "significant support" for undergraduate scholarships, student housing, and the Texas Advanced Computing Center for supercomputing research.

Both the new research campus and the UT Dell Medical Center will integrate advanced computing into their research and practices. At the medical center, the university hopes that will lead to "earlier detection, more precise and personalized care, and better health outcomes." The University of Texas MD Anderson Cancer Center will also be integrated into the new medical center.

That comes with a numeric goal measured in 10s: raise $10 billion and rank among the top 10 medical centers in the U.S., both in the next decade.

In the shorter term, the university will break ground on the medical center with architecture firm Skidmore, Owings & Merrill (SOM) "later this year."

“UT Austin, where Dell Technologies was founded from a dorm room, has always been a place where bold ideas become real-world impact,” said Michael and Susan Dell in a joint statement.

They continued, “What makes this moment so meaningful is the opportunity to build something that brings every part of the journey together — from how students learn, to how discoveries are made, to how care reaches families. By bringing together medicine, science and computing in one campus designed for the AI era, UT can create more opportunity, deliver better outcomes, and build a stronger future for communities across Texas and beyond.”

This is the second major gift this year for the planned multibillion-dollar medical center. In January, Tench Coxe, a former venture capitalist who’s a major shareholder in chipmaking giant Nvidia, and Simone Coxe, co-founder and former CEO of the Blanc & Otus PR firm, contributed $100 million$100 million.

Baylor scientist lands $2M grant to explore links between viruses and Alzheimer’s

Alzheimer’s research

A Baylor College of Medicine scientist will begin exploring the possible link between Alzheimer’s disease and viral infections thanks to a $2 million grant awarded in March.

Dr. Ryan S. Dhindsa is an assistant professor of pathology & immunology at Baylor and a principal investigator at Texas Children’s Duncan Neurological Research Institute (Duncan NRI). He hypothesizes that Alzheimer’s may have some link to previous viral infections contracted by the patient. To study this intriguing possibility, the American Brain Foundation has gifted him the Cure One, Cure Many award in neuroinflammation.

“It is an honor to receive this support from the Cure One, Cure Many Award. Viral infections are emerging as a major, underappreciated driver of Alzheimer's disease, and this award will allow our team to conduct the most comprehensive screen of viral exposures and host genetics in Alzheimer's to date, spanning over a million individuals,” Dhindsa said in a news release. “Our goal is to identify which viruses matter most, why some people are more vulnerable than others, and ultimately move the field closer to new therapeutic strategies for patients.”

Roughly 150 million people worldwide will suffer from Alzheimer’s by 2050, making it the most common cause of dementia in the world. Despite this, scientists are still at a loss as to what exactly causes it.

Dhindsa’s research is part of a new range of theories that certain viral infections may trigger Alzheimer’s. His team will take a two-fold approach. First, they will analyze the medical records of more than a million individuals looking for patterns. Second, they will analyze viral DNA in stem cell-derived brain cells to see how the infections could contribute to neurological decay. The scale of the genomic data gathering is unprecedented and may highlight a link that traditional studies have missed.

Also joining the project are Dr. Caleb Lareau of Memorial Sloan Kettering Cancer Center and Dr. Artem Babaian of the University of Toronto. Should a link be found, it would open the door to using anti-virals to prevent or treat Alzheimer’s.